OLB) has unveiled plans to raise around £4.1 million through a share placing and subscriptions, with the funds earmarked for clinical trials of its experimental treatments in cancer immunotherapy and obesity. The new investment will support the next stage of development for two of the company's lead candidates: a drug designed to prevent a serious side effect of cancer treatment, and a new oral formulation targeting the weight-loss market. 